Bausch + Lomb (NYSE:BLCO) Issues Quarterly Earnings Results, Beats Estimates By $0.13 EPS

Bausch + Lomb (NYSE:BLCO) issued its earnings results on Wednesday. The company reported $0.34 earnings per share for the quarter, topping analysts’ consensus estimates of $0.21 by $0.13, FiscalAI reports. The business had revenue of $1.38 billion during the quarter, compared to analyst estimates of $1.37 billion. Bausch + Lomb had a positive return on equity of 5.02% and a negative net margin of 2.05%. Bausch + Lomb’s revenue was up 7.3% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.18 EPS.

Here are the key takeaways from Bausch + Lomb’s conference call:

• Strong third-quarter results: Constant-currency revenue rose 8% to $1.375 billion, adjusted EBITDA increased 34% to $325 million, and adjusted EBITDA margin expanded 460 basis points to 23.6%.
• Management raised 2026 guidance for the third time, increasing revenue guidance to $5.45 billion–$5.55 billion and adjusted EBITDA guidance to $1.09 billion–$1.14 billion, implying approximately 20.3% full-year EBITDA margin.
• Growth was broad-based across all segments, led by Pharmaceuticals at 11%, Surgical at 9%, and Vision Care at 6%; key products included MIEBO, LUMIFY, Daily SiHy contact lenses, and premium IOLs.
• Cash generation strengthened, with $233 million of operating cash flow and $178 million of free cash flow, reducing net leverage to 4.1 times from 5.7 times a year earlier and keeping the company on track toward its 3.5-times target.
• Tom Appio is serving as interim CEO following a mutually agreed leadership transition. He emphasized operational efficiency, disciplined capital allocation, debt reduction, and advancing the innovation pipeline, while providing limited detail on the reasons for the change.

Bausch + Lomb Stock Performance

BLCO traded down $0.32 during trading on Friday, hitting $20.08. The stock had a trading volume of 617,562 shares, compared to its average volume of 467,310. Bausch + Lomb has a twelve month low of $14.44 and a twelve month high of $21.36. The company’s 50-day moving average price is $17.30 and its 200 day moving average price is $16.67. The firm has a market capitalization of $7.18 billion, a P/E ratio of -64.89, a PEG ratio of 0.64 and a beta of 0.56. The company has a debt-to-equity ratio of 0.79, a quick ratio of 1.02 and a current ratio of 1.55.

Bausch + Lomb News Summary

Here are the key news stories impacting Bausch + Lomb this week:

• Positive Sentiment: Quarterly profit exceeded expectations. Bausch + Lomb reported third-quarter adjusted EPS of $0.34, well above the $0.21 analyst consensus, while revenue increased 7.3% year over year to approximately $1.38 billion, slightly ahead of estimates. Bausch + Lomb Q3 2026 profit report
• Positive Sentiment: Management raised 2026 guidance. The company now expects revenue of $5.450 billion to $5.550 billion and adjusted EBITDA of $1.090 billion to $1.140 billion, citing continued momentum from its Vision ’27 strategy. The upgraded outlook reinforces expectations for improving growth and profitability. Bausch + Lomb raises 2026 guidance
• Positive Sentiment: RBC increased its price target to $23 from $21 and maintained an “outperform” rating, implying additional upside and signaling confidence in the earnings trajectory. RBC raises Bausch + Lomb price target
• Neutral Sentiment: JPMorgan raised its target to $22 from $16 but retained a “neutral” rating. Deutsche Bank lifted its target to $20 from $16 while keeping a “hold” rating, suggesting analysts see improved fundamentals but are not uniformly bullish.
• Neutral Sentiment: Wells Fargo increased its target to $19 from $18 but maintained an “equal weight” rating. Its target remains below the recent trading level, highlighting valuation concerns despite the better results.

Insider Transactions at Bausch + Lomb

In other news, CAO Frederick Munsch sold 52,900 shares of the business’s stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $16.78, for a total transaction of $887,662.00. Following the sale, the chief accounting officer owned 45,831 shares of the company’s stock, valued at $769,044.18. The trade was a 53.58% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Eschenbach Andrew C. Von sold 6,059 shares of the company’s stock in a transaction on Friday, August 7th. The shares were sold at an average price of $16.58, for a total value of $100,458.22. Following the completion of the sale, the director owned 63,733 shares in the company, valued at $1,056,693.14. This represents a 8.68% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 71,459 shares of company stock worth $1,194,370. 1.45% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on the stock. HC Wainwright reissued a “buy” rating and set a $21.00 target price on shares of Bausch + Lomb in a research note on Friday, August 28th. UBS Group initiated coverage on Bausch + Lomb in a report on Thursday, July 30th. They issued a “buy” rating and a $21.00 price target for the company. Evercore set a $17.00 price target on shares of Bausch + Lomb in a research report on Monday, July 6th. Citigroup raised their price target on Bausch + Lomb from $21.00 to $23.00 and gave the stock a “buy” rating in a research report on Thursday. Finally, Royal Bank Of Canada increased their target price on Bausch + Lomb from $21.00 to $23.00 and gave the stock an “outperform” rating in a research note on Thursday. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, seven have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $20.75.

Bausch + Lomb Company Profile

Bausch + Lomb Corporation (NYSE: BLCO) is a global eye-health company that develops, manufactures and markets products for vision care, ophthalmic pharmaceuticals and eye surgery. The company serves consumers, eye-care professionals, hospitals and surgical centers through a portfolio spanning contact lenses, contact-lens care products, prescription medicines, over-the-counter eye-care products and surgical equipment.

Its vision-care portfolio includes the Biotrue and INFUSE contact-lens brands, as well as solutions and other products used to clean and maintain contact lenses.